{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:44:11Z","timestamp":1792122251305,"version":"4.4.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T00:00:00Z","timestamp":1367280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/nrd4001","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T03:11:50Z","timestamp":1367291510000},"page":"388-404","source":"Crossref","is-referenced-by-count":820,"title":["Advances in the development of new tuberculosis drugs and treatment regimens"],"prefix":"10.1038","volume":"12","author":[{"given":"Alimuddin","family":"Zumla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart T.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,30]]},"reference":[{"key":"BFnrd4001_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMra1200894","volume":"368","author":"A Zumla","year":"2013","unstructured":"Zumla, A., Raviglione, M., Hafner, R. & von Reyn, C. F. Tuberculosis. N. Engl. J. Med. 368, 745\u2013755 (2013). An important update of current concepts on the clinical, epidemiological and management aspects of tuberculosis.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/B978-1-4160-3988-4.00006-8","volume-title":"Tuberculosis: A Comprehensive Clinical Reference","author":"JM Grange","year":"2009","unstructured":"Grange, J. M. in Tuberculosis: A Comprehensive Clinical Reference (eds Schaaf, S. & Zumla, A. I.) 44\u201359 (Saunders, 2009)."},{"key":"BFnrd4001_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.282.7.677","volume":"282","author":"C Dye","year":"1999","unstructured":"Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677\u2013686 (1999).","journal-title":"JAMA"},{"key":"BFnrd4001_CR4","doi-asserted-by":"crossref","unstructured":"Diel, R. et al. Old ideas to innovate TB control: preventive treatment to achieve elimination. Eur. Respir. J. 8 Feb 2013 (10.1183\/09031936.00205512).","DOI":"10.1183\/09031936.00205512"},{"key":"BFnrd4001_CR5","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/S0140-6736(12)60727-2","volume":"379","author":"M Raviglione","year":"2012","unstructured":"Raviglione, M. et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379, 1902\u20131913 (2012).","journal-title":"Lancet"},{"key":"BFnrd4001_CR6","unstructured":"World Health Organization. Global Tuberculosis Report 2012 (WHO, 2012)."},{"key":"BFnrd4001_CR7","unstructured":"European Centre for Disease Prevention and Control\/WHO Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe (European Centre for Disease Prevention and Control, 2012)."},{"key":"BFnrd4001_CR8","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1017\/S095026881100286X","volume":"140","author":"AN Hill","year":"2012","unstructured":"Hill, A. N., Becerra, J. & Castro, K. G. Modelling tuberculosis trends in the USA. Epidemiol. Infect. 140, 1862\u20131872 (2012).","journal-title":"Epidemiol. Infect."},{"key":"BFnrd4001_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.339.6116.130","volume":"339","author":"J Cohen","year":"2013","unstructured":"Cohen, J. Infectious disease. Approval of novel TB drug celebrated \u2014 with restraint. Science 339, 130 (2013).","journal-title":"Science"},{"key":"BFnrd4001_CR10","unstructured":"World Health Organization. Treatment of Tuberculosis Guidelines 4th edn (WHO, 2010)."},{"key":"BFnrd4001_CR11","unstructured":"Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC) 2nd edn (Tuberculosis Coalition for Technical Assistance, 2009)"},{"key":"BFnrd4001_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1164\/rccm.200904-0536OC","volume":"180","author":"JL Johnson","year":"2009","unstructured":"Johnson, J. L. et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am. J. Respir. Crit. Care Med. 180, 558\u2013563 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrd4001_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1001\/jama.2011.436","volume":"305","author":"C Lienhardt","year":"2011","unstructured":"Lienhardt, C. et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial. JAMA 305, 1415\u20131423 (2011).","journal-title":"JAMA"},{"key":"BFnrd4001_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/cid\/cis487","volume":"55","author":"KE Dooley","year":"2012","unstructured":"Dooley, K. E. et al. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin. Infect. Dis. 55, 572\u2013581 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd4001_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1183\/09031936.00073611","volume":"38","author":"D Falzon","year":"2011","unstructured":"Falzon, D. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 38, 516\u2013528 (2011).","journal-title":"Eur. Respir. J."},{"key":"BFnrd4001_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1473-3099(13)70008-2","volume":"13","author":"SD Lawn","year":"2013","unstructured":"Lawn, S. D. & Zumla, A. Advances in tuberculosis diagnostics: the Xpert MTB\/RIF assay and future prospects for a point-of-care test. Lancet Infect. Dis. 13, 349\u2013361 (2013). A critical review of the Xpert MTB\/RIF assay and the advantages and limitations of its utility in clinical practice.","journal-title":"Lancet Infect. Dis."},{"key":"BFnrd4001_CR17","doi-asserted-by":"crossref","unstructured":"Weyer, K. et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert\u00aeMTB\/RIF. Eur. Respir. J. 22 Nov 2012 (10.1183\/09031936.00157212).","DOI":"10.1183\/09031936.00157212"},{"key":"BFnrd4001_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","volume":"368","author":"NR Gandhi","year":"2006","unstructured":"Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575\u20131580 (2006).","journal-title":"Lancet"},{"key":"BFnrd4001_CR19","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/S0140-6736(10)60492-8","volume":"375","author":"K Dheda","year":"2010","unstructured":"Dheda, K. et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 375, 1798\u20131807 (2010).","journal-title":"Lancet"},{"key":"BFnrd4001_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1086\/653115","volume":"51","author":"KR Jacobson","year":"2010","unstructured":"Jacobson, K. R., Tierney, D. B., Jeon, C. Y., Mitnick, C. D. & Murray, M. B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 51, 6\u201314 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd4001_CR21","unstructured":"Migliori, G. B. et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur. Respir. J. 11 Oct 2012 (10.1183\/09031936.00136312)."},{"key":"BFnrd4001_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/cid\/cir889","volume":"54","author":"ZF Udwadia","year":"2012","unstructured":"Udwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54, 579\u2013581 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd4001_CR23","unstructured":"World Health Organization. \u201cTotally Drug-Resistant TB\u201d: a WHO consultation on the diagnostic definition and treatment options. World Health Organization [online] , (2012)."},{"key":"BFnrd4001_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.mib.2011.07.022","volume":"14","author":"ST Cole","year":"2011","unstructured":"Cole, S. T. & Riccardi, G. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 14, 570\u2013576 (2011).","journal-title":"Curr. Opin. Microbiol."},{"key":"BFnrd4001_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature09657","volume":"469","author":"A Koul","year":"2011","unstructured":"Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. Nature 469, 483\u2013490 (2011).","journal-title":"Nature"},{"key":"BFnrd4001_CR26","unstructured":"Global-Alliance for TB Drug Development. Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb.) 81, (Suppl. 1), 1\u201352 (2001)."},{"key":"BFnrd4001_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrmicro2236","volume":"7","author":"CE Barry","year":"2009","unstructured":"Barry, C. E. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845\u2013855 (2009).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrd4001_CR28","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","volume":"167","author":"A Jindani","year":"2003","unstructured":"Jindani, A., Dor\u00e9, C. J. & Mitchison, D. A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167, 1348\u20131354 (2003).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl. 1","key":"BFnrd4001_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1472-9792(08)70038-6","volume":"88","author":"PR Donald","year":"2008","unstructured":"Donald, P. R. & Diacon, A. H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb.) 88, (Suppl. 1), 75\u201383 (2008).","journal-title":"Tuberculosis (Edinb.)"},{"key":"BFnrd4001_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","volume":"169","author":"EL Nuermberger","year":"2004","unstructured":"Nuermberger, E. L. et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169, 421\u2013426 (2004).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrd4001_CR31","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","volume":"375","author":"Z Ma","year":"2010","unstructured":"Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100\u20132109 (2010).","journal-title":"Lancet"},{"key":"BFnrd4001_CR32","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1371\/journal.pmed.0040344","volume":"4","author":"IM Rosenthal","year":"2007","unstructured":"Rosenthal, I. M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4, e344 (2007).","journal-title":"PLoS Med."},{"key":"BFnrd4001_CR33","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling, T. R. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 365, 2155\u20132166 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR34","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1128\/AAC.01474-06","volume":"51","author":"AH Diacon","year":"2007","unstructured":"Diacon, A. H. et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51, 2994\u20132996 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR35","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1093\/cid\/cir184","volume":"52","author":"J van Ingen","year":"2011","unstructured":"van Ingen, J. et al. Why do we use 600\u00a0mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52, e194\u2013e199 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd4001_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223\u2013227 (2005). A landmark paper describing the discovery and development of bedaquiline and the validation of a novel yet ubiquitous new drug target for TB.","journal-title":"Science"},{"key":"BFnrd4001_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jac\/dks389","volume":"68","author":"T Dey","year":"2013","unstructured":"Dey, T. et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 68, 284\u2013293 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrd4001_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Van Deun","year":"2010","unstructured":"Van Deun, A. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182, 684\u2013692 (2010). An observational \u201cBangladesh\u201d standardized regimen study, with a duration of 9\u201312 months, that included gatifloxacin, ethambutol, pyrazinamide and clofazimine throughout, supplemented by kanamycin, prothionamide and isoniazid. During an intensive phase of 4 months this regimen achieved <1% failure and \u223c90% relapse-free cure.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrd4001_CR39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1128\/AAC.01897-12","volume":"57","author":"RK Verma","year":"2013","unstructured":"Verma, R. K. et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob. Agents Chemother. 57, 1050\u20131052 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR40","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1128\/AAC.01125-12","volume":"56","author":"M Zhang","year":"2012","unstructured":"Zhang, M. et al. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56, 5782\u20135789 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0732-8893(91)90002-W","volume":"14","author":"DR Ashtekar","year":"1991","unstructured":"Ashtekar, D. R. et al. Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 14, 465\u2013471 (1991).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFnrd4001_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jac\/dki148","volume":"56","author":"J Fortun","year":"2005","unstructured":"Fortun, J. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56, 180\u2013185 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrd4001_CR43","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee, M. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367, 1508\u20131518 (2012). A demonstration that linezolid, a drug with poor EBA, can improve the prognosis of patients with XDR-TB, thus providing hope that next-generation oxazolidinones may be even better.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR44","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00022912","volume":"40","author":"G Sotgiu","year":"2012","unstructured":"Sotgiu, G. et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 40, 1430\u20131442 (2012).","journal-title":"Eur. Respir. J."},{"key":"BFnrd4001_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/AAC.01179-10","volume":"55","author":"RS Wallis","year":"2010","unstructured":"Wallis, R. S. et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55, 567\u2013574 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/655471","volume":"202","author":"RS Wallis","year":"2010","unstructured":"Wallis, R. S. et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202, 745\u2013751 (2010).","journal-title":"J. Infect. Dis."},{"key":"BFnrd4001_CR47","doi-asserted-by":"publisher","first-page":"e30479","DOI":"10.1371\/journal.pone.0030479","volume":"7","author":"RS Wallis","year":"2012","unstructured":"Wallis, R. S. et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE 7, e30479 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrd4001_CR48","volume-title":"51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"S Reele","year":"2011","unstructured":"Reele, S. et al. A 14-day multiple ascending dose study: AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB) (Abstract A1-1735). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy [online] , (2011)."},{"key":"BFnrd4001_CR49","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1126\/science.1167498","volume":"323","author":"JE Hugonnet","year":"2009","unstructured":"Hugonnet, J. E. et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323, 1215\u20131218 (2009).","journal-title":"Science"},{"key":"BFnrd4001_CR50","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2958.2012.08199.x","volume":"86","author":"P Kumar","year":"2012","unstructured":"Kumar, P. et al. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86, 367\u2013381 (2012).","journal-title":"Mol. Microbiol."},{"key":"BFnrd4001_CR51","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/INF.0b013e3182154b05","volume":"30","author":"N Dauby","year":"2011","unstructured":"Dauby, N., Muylle, I., Mouchet, F., Sergysels, R. & Payen, M. C. Meropenem\/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J. 30, 812\u2013813 (2011).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"BFnrd4001_CR52","doi-asserted-by":"crossref","unstructured":"De Lorenzo, S. et al. Efficacy and safety of meropenem\/clavunate added to linezolid containing regimens in the treatment of M\/XDR-TB. Eur. Respir. J. 20 Sept 2012 (10.1183\/09031936.00124312).","DOI":"10.1183\/09031936.00124312"},{"key":"BFnrd4001_CR53","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","volume":"3","author":"A Koul","year":"2007","unstructured":"Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323\u2013324 (2007).","journal-title":"Nature Chem. Biol."},{"key":"BFnrd4001_CR54","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1128\/AAC.01393-08","volume":"53","author":"AC Haagsma","year":"2009","unstructured":"Haagsma, A. C. et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53, 1290\u20131292 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR55","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1128\/AAC.01611-09","volume":"54","author":"E Huitric","year":"2009","unstructured":"Huitric, E. et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 54, 1022\u20131028 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR56","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1128\/AAC.01039-12","volume":"57","author":"G Biukovic","year":"2013","unstructured":"Biukovic, G. et al. Variations of subunit \u03b5 of the Mycobacterium tuberculosis F1F0 ATP synthase and a novel model for mechanism of action of the TB drug TMC207. Antimicrob. Agents Chemother. 57, 168\u2013176 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR57","doi-asserted-by":"publisher","first-page":"25273","DOI":"10.1074\/jbc.M803899200","volume":"283","author":"A Koul","year":"2008","unstructured":"Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273\u201325280 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrd4001_CR58","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"SP Rao","year":"2008","unstructured":"Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105, 11945\u201311950 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4001_CR59","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"360","author":"AH Diacon","year":"2009","unstructured":"Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397\u20132405 (2009). An important publication documenting the considerable impact of bedaquiline on the prognosis of patients with MDR-TB and the value of testing new drugs in MDR cohorts.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1164\/rccm.200711-1736OC","volume":"179","author":"N Veziris","year":"2009","unstructured":"Veziris, N. et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 179, 75\u201379 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrd4001_CR61","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1128\/JCM.00177-08","volume":"46","author":"N Lounis","year":"2008","unstructured":"Lounis, N. et al. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J. Clin. Microbiol. 46, 2212\u20132215 (2008).","journal-title":"J. Clin. Microbiol."},{"key":"BFnrd4001_CR62","doi-asserted-by":"publisher","first-page":"14188","DOI":"10.1073\/pnas.1121497109","volume":"109","author":"PL Lin","year":"2012","unstructured":"Lin, P. L. et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl Acad. Sci. USA 109, 14188\u201314193 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4001_CR63","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"CK Stover","year":"2000","unstructured":"Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962\u2013966 (2000).","journal-title":"Nature"},{"key":"BFnrd4001_CR64","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","volume":"3","author":"M Matsumoto","year":"2006","unstructured":"Matsumoto, M. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, e466 (2006).","journal-title":"PLoS Med."},{"key":"BFnrd4001_CR65","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1073\/pnas.0508392103","volume":"103","author":"UH Manjunatha","year":"2006","unstructured":"Manjunatha, U. H. et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431\u2013436 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4001_CR66","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","volume":"322","author":"R Singh","year":"2008","unstructured":"Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392\u20131395 (2008). An important publication documenting a novel M. tuberculosis killing mechanism mediated by PA-824 (and later by delaminid) that provides proof of concept for developing novel NO donor drugs for treating TB.","journal-title":"Science"},{"key":"BFnrd4001_CR67","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1128\/AAC.00488-06","volume":"50","author":"UH Manjunatha","year":"2006","unstructured":"Manjunatha, U. H. et al. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob. Agents Chemother. 50, 3350\u20133354 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR68","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/jac\/dkn307","volume":"62","author":"JG Hurdle","year":"2008","unstructured":"Hurdle, J. G. et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother. 62, 1037\u20131045 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrd4001_CR69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4161\/cib.2.3.7926","volume":"2","author":"U Manjunatha","year":"2009","unstructured":"Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215\u2013218 (2009).","journal-title":"Commun. Integr. Biol."},{"key":"BFnrd4001_CR70","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1128\/AAC.06125-11","volume":"56","author":"A Diacon","year":"2012","unstructured":"Diacon, A. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824; Antimicrob. Agents Chemother. 56, 3027\u20133031 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR71","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","volume":"380","author":"AH Diacon","year":"2012","unstructured":"Diacon, A. H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986\u2013993 (2012). A seminal study describing how the use of EBA with combination therapies has the potential to reduce the time needed for developing new multidrug regimens.","journal-title":"Lancet"},{"key":"BFnrd4001_CR72","doi-asserted-by":"publisher","first-page":"949","DOI":"10.5588\/ijtld.10.0616","volume":"15","author":"AH Diacon","year":"2011","unstructured":"Diacon, A. H. et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 15, 949\u2013954 (2011).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnrd4001_CR73","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler, M. T. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366, 2151\u20132160 (2012). An encouraging publication demonstrating that delamanid could enhance treatment options for patients with MDR-TB.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR74","doi-asserted-by":"crossref","unstructured":"Skripconoka, V. et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur. Respir. J. 27 Sept 2012 (10.1183\/09031936.00125812).","DOI":"10.1183\/09031936.00125812"},{"key":"BFnrd4001_CR75","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/cc020071p","volume":"5","author":"RE Lee","year":"2003","unstructured":"Lee, R. E. et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5, 172\u2013187 (2003).","journal-title":"J. Comb. Chem."},{"key":"BFnrd4001_CR76","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1128\/AAC.05708-11","volume":"56","author":"K Tahlan","year":"2012","unstructured":"Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797\u20131809 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR77","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1128\/AAC.01601-09","volume":"54","author":"VM Reddy","year":"2010","unstructured":"Reddy, V. M., Einck, L., Andries, K. & Nacy, C. A. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54, 2840\u20132846 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR78","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nchembio.794","volume":"8","author":"AE Grzegorzewicz","year":"2012","unstructured":"Grzegorzewicz, A. E. et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nature Chem. Biol. 8, 334\u2013341 (2012).","journal-title":"Nature Chem. Biol."},{"key":"BFnrd4001_CR79","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1128\/AAC.05270-11","volume":"56","author":"V La Rosa","year":"2012","unstructured":"La Rosa, V. et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56, 324\u2013331 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR80","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1021\/cb300151m","volume":"7","author":"SA Stanley","year":"2012","unstructured":"Stanley, S. A. et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377\u20131384 (2012).","journal-title":"ACS Chem. Biol."},{"key":"BFnrd4001_CR81","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"V Makarov","year":"2009","unstructured":"Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801\u2013804 (2009). A landmark paper presenting both a new chemical entity and a novel drug target for TB therapy.","journal-title":"Science"},{"key":"BFnrd4001_CR82","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1128\/AAC.01676-09","volume":"54","author":"MR Pasca","year":"2010","unstructured":"Pasca, M. R. et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother. 54, 1616\u20131618 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR83","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1128\/AAC.01476-12","volume":"56","author":"B Lechartier","year":"2012","unstructured":"Lechartier, B., Hartkoorn, R. C. & Cole, S. T. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 5790\u20135793 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR84","doi-asserted-by":"publisher","first-page":"150ra121","DOI":"10.1126\/scitranslmed.3004395","volume":"4","author":"J Neres","year":"2012","unstructured":"Neres, J. et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 4, 150ra121 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd4001_CR85","doi-asserted-by":"publisher","first-page":"13663","DOI":"10.1021\/ja106357w","volume":"132","author":"C Trefzer","year":"2010","unstructured":"Trefzer, C. et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-\u03b2-d-ribose 2\u2032-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 132, 13663\u201313665 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnrd4001_CR86","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1021\/ja211042r","volume":"134","author":"C Trefzer","year":"2012","unstructured":"Trefzer, C. et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-\u03b2-d-ribofuranose 2\u2032-oxidase DprE1. J. Am. Chem. Soc. 134, 912\u2013915 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnrd4001_CR87","doi-asserted-by":"publisher","first-page":"e1000645","DOI":"10.1371\/journal.ppat.1000645","volume":"5","author":"T Christophe","year":"2009","unstructured":"Christophe, T. et al. High content screening identifies decaprenyl-phosphoribose 2\u2032 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645 (2009).","journal-title":"PLoS Pathog."},{"key":"BFnrd4001_CR88","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.tube.2010.09.001","volume":"90","author":"S Magnet","year":"2010","unstructured":"Magnet, S. et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb.) 90, 354\u2013360 (2010).","journal-title":"Tuberculosis (Edinb.)"},{"key":"BFnrd4001_CR89","first-page":"241","volume":"14","author":"AJ Nunn","year":"2010","unstructured":"Nunn, A. J., Phillips, P. P. & Mitchison, D. A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int. J. Tuberc. Lung Dis. 14, 241\u2013242 (2010).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFnrd4001_CR90","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1745-6215-13-61","volume":"13","author":"CS Merle","year":"2012","unstructured":"Merle, C. S. et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the gatifloxacin for TB (OFLOTUB) project. Trials 13, 61 (2012).","journal-title":"Trials"},{"issue":"Suppl. 2","key":"BFnrd4001_CR91","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/infdis\/jis041","volume":"205","author":"PP Phillips","year":"2012","unstructured":"Phillips, P. P. et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis. 205, (Suppl. 2), 250\u2013257 (2012).","journal-title":"J. Infect. Dis."},{"key":"BFnrd4001_CR92","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1473-3099(13)70034-3","volume":"13","author":"R Wallis","year":"2013","unstructured":"Wallis, R. et al. Tuberculosis biomarkers discovery: developments, needs and challenges. Lancet Infect. Dis. 13, 362\u2013372 (2013). An important review of the latest information on progress on TB biomarkers development.","journal-title":"Lancet Infect. Dis."},{"key":"BFnrd4001_CR93","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1473-3099(10)70071-2","volume":"10","author":"DJ Horne","year":"2010","unstructured":"Horne, D. J. et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10, 387\u2013394 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"BFnrd4001_CR94","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nri2960","volume":"11","author":"G Walzl","year":"2011","unstructured":"Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J. & Zumla, A. Immunological biomarkers of tuberculosis. Nature Rev. Immunol. 11, 343\u2013354 (2011).","journal-title":"Nature Rev. Immunol."},{"issue":"Suppl. 2","key":"BFnrd4001_CR95","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/infdis\/jir860","volume":"205","author":"R McNerney","year":"2012","unstructured":"McNerney, R. et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J. Infect. Dis. 205 (Suppl. 2), 147\u2013158 (2012).","journal-title":"J. Infect. Dis."},{"key":"BFnrd4001_CR96","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1164\/rccm.201105-0827WS","volume":"184","author":"P Nahid","year":"2011","unstructured":"Nahid, P. et al. CDC\/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am. J. Respir. Crit. Care Med. 184, 972\u2013979 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrd4001_CR97","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1183\/09031936.00145411","volume":"39","author":"A Skrahina","year":"2012","unstructured":"Skrahina, A. et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur. Respir. J. 39, 1425\u20131431 (2012).","journal-title":"Eur. Respir. J."},{"key":"BFnrd4001_CR98","unstructured":"Abubakar, I. et al. Drug resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis. 24 Mar 2013 (10.1016\/S1473-3099(13)70030-6)."},{"key":"BFnrd4001_CR99","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3181\/00379727-55-14461","volume":"55","author":"A Schatz","year":"1944","unstructured":"Schatz, A., Bugie, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55, 66\u201369 (1944).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnrd4001_CR100","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJM194608152350704","volume":"235","author":"JD Wassersug","year":"1946","unstructured":"Wassersug, J. D. Pulmonary tuberculosis. N. Engl. J. Med. 235, 220\u2013229 (1946).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR101","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/bmj.1.4602.497-d","volume":"1","author":"G Marshall","year":"1949","unstructured":"Marshall, G. Streptomycin in the treatment of pulmonary tuberculosis. A Medical Research Council investigation. BMJ 1, 382\u2013386 (1949).","journal-title":"BMJ"},{"key":"BFnrd4001_CR102","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603\u2013662 (2003).","DOI":"10.1164\/rccm.167.4.603"},{"key":"BFnrd4001_CR103","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1517\/14740338.2011.546783","volume":"10","author":"TN Gengiah","year":"2011","unstructured":"Gengiah, T. N., Gray, A. L., Naidoo, K. & Karim, Q. A. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin. Drug Saf. 10, 559\u2013574 (2011).","journal-title":"Expert Opin. Drug Saf."},{"key":"BFnrd4001_CR104","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","volume":"365","author":"DV Havlir","year":"2011","unstructured":"Havlir, D. V. et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 365, 1482\u20131491 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR105","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","volume":"365","author":"FX Blanc","year":"2011","unstructured":"Blanc, F. X. et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365, 1471\u20131481 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR106","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1056\/NEJMp1300458","volume":"368","author":"KM De Cock","year":"2013","unstructured":"De Cock, K. M. & El-Sadr, W. M. When to start ART in Africa \u2014 an urgent research priority. N. Engl. J. Med. 368, 886\u2013889 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4001_CR107","doi-asserted-by":"publisher","first-page":"e1002262","DOI":"10.1371\/journal.ppat.1002262","volume":"7","author":"S Subbian","year":"2011","unstructured":"Subbian, S. et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 7, e1002262 (2011).","journal-title":"PLoS Pathog."},{"key":"BFnrd4001_CR108","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cell.2011.12.023","volume":"148","author":"DM Tobin","year":"2012","unstructured":"Tobin, D. M. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434\u2013446 (2012).","journal-title":"Cell"},{"key":"BFnrd4001_CR109","doi-asserted-by":"publisher","first-page":"e39680","DOI":"10.1371\/journal.pone.0039680","volume":"7","author":"C Skerry","year":"2012","unstructured":"Skerry, C., Harper, J., Klunk, M., Bishai, W. R. & Jain, S. K. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS ONE 7, e39680 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrd4001_CR110","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","volume":"10","author":"RJ Napier","year":"2012","unstructured":"Napier, R. J. et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10, 475\u2013485 (2012).","journal-title":"Cell Host Microbe"},{"key":"BFnrd4001_CR111","unstructured":"Ivanyi, I. & Zumla, A. Non-steroidal anti-inflammatory drugs for adjunctive tuberculosis treatment. J. Infect. Dis. 5 Apr 2013 (10.1093\/infdis\/jit153)."},{"key":"BFnrd4001_CR112","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/jac\/dkl500","volume":"59","author":"L Amaral","year":"2007","unstructured":"Amaral, L., Martins, M. & Viveiros, M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59, 1237\u20131246 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrd4001_CR113","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","volume":"145","author":"KN Adams","year":"2011","unstructured":"Adams, K. N. et al. Drug tolerance in replicating mycobacteria mediate macrophage-induced efflux mechanism. Cell 145, 39\u201353 (2011).","journal-title":"Cell"},{"key":"BFnrd4001_CR114","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1128\/AAC.01696-12","volume":"57","author":"LE Lim","year":"2013","unstructured":"Lim, L. E. et al. Anthelmintic avermectins kill M. tuberculosis, including multidrug-resistant clinical strains. Antimicrob. Agents Chemother. 57, 1040\u20131046 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR115","doi-asserted-by":"publisher","first-page":"e30749","DOI":"10.1371\/journal.pone.0030749","volume":"7","author":"M Maiga","year":"2012","unstructured":"Maiga, M. et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE 7, e30749 (2012).","journal-title":"PLoS ONE"},{"issue":"Suppl. 2","key":"BFnrd4001_CR116","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/infdis\/jis197","volume":"205","author":"M Uhlin","year":"2012","unstructured":"Uhlin, M., Andersson, J., Zumla, A. & Maeurer, M. Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 205 (Suppl. 2), 325\u2013334 (2012).","journal-title":"J. Infect. Dis."},{"key":"BFnrd4001_CR117","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.4049\/jimmunol.1201538","volume":"189","author":"H Bruns","year":"2012","unstructured":"Bruns, H. et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 189, 4069\u20134078 (2012).","journal-title":"J. Immunol."},{"key":"BFnrd4001_CR118","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nature06345","volume":"450","author":"C Kuijl","year":"2007","unstructured":"Kuijl, C. et al. Intracellular bacterial growth is controlled by a kinase network around PKB\/AKT1. Nature. 450, 725\u2013730 (2007).","journal-title":"Nature."},{"key":"BFnrd4001_CR119","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nrmicro1065","volume":"3","author":"HI Boshoff","year":"2005","unstructured":"Boshoff, H. I. & Barry, C. E. 3rd. Tuberculosis \u2014 metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70\u201380 (2005).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnrd4001_CR120","first-page":"313","volume-title":"Bacterial Resistance to Antimicrobials","author":"AS Pym","year":"2008","unstructured":"Pym, A. S. & Cole, S. T. in Bacterial Resistance to Antimicrobials 2nd Edn (eds Wax, R. G., Lewis, K., Salyers, A. A. & Taber, H.) 313\u2013342 (CRC, 2008)."},{"key":"BFnrd4001_CR121","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1208813","volume":"333","author":"W Shi","year":"2011","unstructured":"Shi, W. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333, 1630\u20131632 (2011).","journal-title":"Science"},{"key":"BFnrd4001_CR122","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1228980","volume":"339","author":"S Chakraborty","year":"2013","unstructured":"Chakraborty, S., Gruber, T., Barry, C. E. 3rd, Boshoff, H. I. & Rhee, K. Y. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339, 88\u201391 (2013).","journal-title":"Science"},{"key":"BFnrd4001_CR123","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/jac\/dks033","volume":"67","author":"FA Sirgel","year":"2012","unstructured":"Sirgel, F. A. et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 67, 1088\u20131093 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrd4001_CR124","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/mdr.2011.0063","volume":"18","author":"FA Sirgel","year":"2012","unstructured":"Sirgel, F. A. et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb. Drug Resist. 18, 193\u2013197 (2012).","journal-title":"Microb. Drug Resist."},{"key":"BFnrd4001_CR125","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1128\/AAC.01326-12","volume":"56","author":"S Salian","year":"2012","unstructured":"Salian, S. et al. Structure\u2013activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups. Antimicrob. Agents Chemother. 56, 6104\u20136108 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR126","doi-asserted-by":"crossref","unstructured":"Global Alliance for TB Drug Development. Cycloserine. Tuberculosis (Edinb.) 88, 100\u2013101 (2008).","DOI":"10.1016\/S1472-9792(08)70007-6"},{"key":"BFnrd4001_CR127","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1128\/AAC.00558-10","volume":"55","author":"JB Bruning","year":"2010","unstructured":"Bruning, J. B., Murillo, A. C., Chacon, O., Barletta, R. G. & Sacchettini, J. C. Structure of the Mycobacterium tuberculosis d-alanine:d-alanine ligase, a target of the antituberculosis drug d-cycloserine. Antimicrob. Agents Chemother. 55, 291\u2013301 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd4001_CR128","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","volume":"360","author":"D Benator","year":"2002","unstructured":"Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528\u2013534 (2002).","journal-title":"Lancet"},{"key":"BFnrd4001_CR129","first-page":"305","volume":"15","author":"KR Steingart","year":"2011","unstructured":"Steingart, K. R., et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuber. Lung Dis. 15, 305\u2013316 (2011).","journal-title":"Int. J. Tuber. Lung Dis."},{"key":"BFnrd4001_CR130","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.1073\/pnas.1205735109","volume":"109","author":"SM Batt","year":"2012","unstructured":"Batt, S. M., et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. USA 109, 11354\u201311359 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd4001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd4001","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd4001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:20:10Z","timestamp":1684452010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd4001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,30]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFnrd4001"],"URL":"https:\/\/doi.org\/10.1038\/nrd4001","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,30]]}}}